These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16702818)

  • 1. Excretion of cytosine arabinoside in saliva after its administration at high doses.
    Mori T; Yamazaki R; Nakazato T; Aisa Y; Enoki S; Arai M; Ikeda Y; Okamoto S
    Anticancer Drugs; 2006 Jun; 17(5):597-8. PubMed ID: 16702818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 3. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
    Tsutsumi H; Kumakawa T; Hirai M; Kikukawa M; Arie Y; Mori M; Kodo H; Nakamura N; Murai Y; Mizutani R
    Nihon Ronen Igakkai Zasshi; 1995 Mar; 32(3):190-4. PubMed ID: 7596061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
    Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
    Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
    Winer ES; Miller KB; Chan GW
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):11-4. PubMed ID: 15934494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
    Heyll A; Aul C; Heyll U; Schneider W
    Haematol Blood Transfus; 1987; 30():322-5. PubMed ID: 3476364
    [No Abstract]   [Full Text] [Related]  

  • 9. Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.
    Murray M; Sarsfield P; Lawlor E; McCann SR
    Ir J Med Sci; 1988 Jul; 157(7):238-41. PubMed ID: 3170148
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM; de Witte T; de Pauw BE; Haanen C
    Neth J Med; 1990 Feb; 36(1-2):19-24. PubMed ID: 2314517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
    Pellier I; Leboucher B; Rachieru P; Ifrah N; Rialland X
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):837-9. PubMed ID: 17164656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anterior uveitis associated with high-dose cytosine arabinoside.
    Fintelmann RE; Qian Y; Skalet A; Jeng BH
    Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
    Phuphanich S; Maria B; Braeckman R; Chamberlain M
    J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
    Bolwell BJ; Cassileth PA; Gale RP
    Leukemia; 1987 Aug; 1(8):575-9. PubMed ID: 3312846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
    Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
    Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.